ストックスクリーナーアプリを入手
41.30
13.74%
4.99
アフターアワーズ：
41.45
0.15
+0.36%
前日終値:
$36.31
開ける：
$41.505
24時間の取引高:
5.89M
Relative Volume:
3.88
時価総額：
$4.34B
収益：
$628.56M
当期純損益:
$141.82M
株価収益率:
32.78
EPS:
1.26
ネットキャッシュフロー:
$142.60M
1週間 パフォーマンス:
+16.70%
1か月 パフォーマンス:
-51.47%
6か月 パフォーマンス:
-40.21%
1年 パフォーマンス:
-30.04%
1日の値動き範囲:
$40.46
$43.50
1週間の範囲:
$33.80
$43.50
52週間の値動き範囲:
$32.99
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
名前
Corcept Therapeutics Inc
セクター
電話
650.688.8803
住所
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
CORT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
41.30 | 3.82B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.35 | 117.00B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 78.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
827.02 | 50.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
370.00 | 48.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.81 | 37.81B | 4.98B | 69.59M | 525.67M | 0.5197 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-31 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | 開始されました | UBS | Neutral |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-06 | アップグレード | Truist | Hold → Buy |
| 2023-04-11 | 開始されました | SVB Securities | Market Perform |
| 2023-04-04 | 開始されました | Piper Sandler | Overweight |
| 2023-02-15 | ダウングレード | Jefferies | Buy → Hold |
| 2022-08-01 | ダウングレード | Truist | Buy → Hold |
| 2022-07-27 | アップグレード | Jefferies | Hold → Buy |
| 2022-06-27 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-02 | 開始されました | Canaccord Genuity | Buy |
| 2022-01-28 | 開始されました | Truist | Buy |
| 2020-08-05 | ダウングレード | Jefferies | Buy → Hold |
| 2019-09-24 | 開始されました | Jefferies | Buy |
| 2019-09-06 | 開始されました | H.C. Wainwright | Buy |
| 2019-02-04 | ダウングレード | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 繰り返されました | Stifel | Hold |
| 2018-05-31 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-09 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 開始されました | Stifel | Buy |
| 2017-02-02 | 開始されました | Ladenburg Thalmann | Buy |
| 2015-04-21 | 開始されました | FBR Capital | Outperform |
| 2014-01-13 | ダウングレード | Stifel | Buy → Hold |
| 2013-08-09 | ダウングレード | Janney | Buy → Neutral |
| 2013-08-09 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2010-01-06 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 開始されました | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | アップグレード | Punk, Ziegel & Co | Mkt Perform → Accumulate |
すべてを表示
Corcept Therapeutics Inc (CORT) 最新ニュース
Corcept’s relacorilant could reach $2.1B ovarian cancer market - BioWorld MedTech
Corcept’s Relacorilant May See All-Comers Advantage, If Approved - Citeline News & Insights
Corcept Therapeutics (NASDAQ:CORT) Shares Gap UpShould You Buy? - MarketBeat
Why Did Corcept Therapeutics Stock Surge Over 14% Today? - Asianet Newsable
Corcept Therapeutics Faces Pressure as Price Target Slashed Amid FDA Setback - StocksToTrade
Corcept Therapeutics (CORT) Sees Significant Stock Surge - GuruFocus
Why Is Corcept Therapeutics Stock Trading Higher Today?Corcept Therapeutics (NASDAQ:CORT) - Benzinga
Eagle Bancorp Posts Upbeat Q4 Results, Joins Corcept Therapeutics, LSI Industries And Other Big Stocks Moving Higher On Thursday - Benzinga
Why This Former Highflying Biotech Just Surged Again - Investor's Business Daily
Corcept Therapeutics (CORT) Surges 25% on Positive Trial Results - GuruFocus
Corcept posts trial win for ovarian cancer therapy (CORT:NASDAQ) - Seeking Alpha
Overall survival primary endpoint met in Corcept's pivotal phase 3 ROSELLA trial of relacorilant in patients with platinum-resistant ovarian cancer - marketscreener.com
Corcept Therapeutics stock soars after cancer drug meets survival endpoint By Investing.com - Investing.com Canada
Corcept Therapeutics Inc Announces Phase 3 Trial Success - TradingView — Track All Markets
In ROSELLA trial, relacorilant added 4.1 months survival in ovarian cancer - Stock Titan
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer - Business Wire
QRG Capital Management Inc. Has $649,000 Stake in Corcept Therapeutics Incorporated $CORT - MarketBeat
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm - PR Newswire
Market Overview: Should you avoid Corcept Therapeutics Incorporated stock right nowWeekly Risk Report & Verified Momentum Watchlists - baoquankhu1.vn
Rally Mode: Will Corcept Therapeutics Incorporated stock hit new highs in YEAR2025 Risk Factors & Verified Short-Term Plans - baoquankhu1.vn
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman - GlobeNewswire Inc.
Zacks Research Has Negative Forecast for CORT Q3 Earnings - MarketBeat
CORT Stock Price, Forecast & Analysis | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - Chartmill
Is Corcept Therapeutics Incorporated (CORT) The Most Promising Growth Stock According to Analysts? - Finviz
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics IncorporatedCORT - PR Newswire
Corcept Therapeutics (NASDAQ:CORT) Lowered to Strong Sell Rating by Zacks Research - MarketBeat
One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit - Yahoo Finance
Corcept Therapeutics (NASDAQ:CORT) Nasdaq Composite Mechanism Strategy - Kalkine Media
CORT Investors Have Opportunity to Join Corcept Therapeutics Inc - GuruFocus
Corcept Therapeutics Under Investigation After FDA Response, Shares Plunge Over 50% - Intellectia AI
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - PR Newswire
Corcept Therapeutics Faces Investigation After FDA Response Letter, Shares Plunge Over 50% - Intellectia AI
DJS Law Group Investigates Corcept Therapeutics for Securities Violations - Intellectia AI
Corcept Therapeutics Incorporated Investigated on Behalf of InvestorsContact the DJS Law Group to Discuss Your Rights – CORT - marketscreener.com
INVESTOR ALERT: Investigation of Corcept Therapeutics Incorporated (CORT) by Holzer & Holzer, LLC - GlobeNewswire
Corcept’s growth hopes dented after FDA rebuff for Cushing’s drug - S&P Global
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50%Hagens Berman - PR Newswire
Corcept Therapeutics (BIT:1CORT) Price Target Decreased by 24.29% to 80.62 - Nasdaq
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AST SpaceMobile, Inc. - GlobeNewswire Inc.
CORT INVESTIGATION: Corcept Therapeutics Investors Should Contact Block & Leviton LLP To Potentially Recover Losses - TradingView — Track All Markets
Inflation Data: Why is Corcept Therapeutics Incorporated stock going upJuly 2025 Opening Moves & Weekly Breakout Watchlists - baoquankhu1.vn
Scott+Scott Attorneys at Law LLP Announces Its Investigation Into Corcept Therapeutics Incorporated (CORT) - marketscreener.com
Bank Watch: Why is Corcept Therapeutics Incorporated stock going upWeekly Volume Report & Expert Curated Trade Ideas - baoquankhu1.vn
CORT Investor ALERT: Corcept Therapeutics Inc. Investigated for Securities Fraud; Investors ... - bdtonline.com
CORT Investor ALERT: Corcept Therapeutics Inc. Investigated - GlobeNewswire
Corcept Insider Transaction Explained After Shares Tumble 50% in One Day - Yahoo Finance
Why Corcept (CORT) stock is trading lower today - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Stockholders to Connect - ACCESS Newswire
H.C. Wainwright lifts Corcept stock target to $115 on drug outlook - MSN
Corcept Therapeutics Inc (CORT) 財務データ
収益
当期純利益
現金流量
EPS
0.46%
0.83%
大文字化:
|
ボリューム (24 時間):